Colonoscopy is regarded as the gold standard for detection of colorectal cancer and its precursors, colorectal adenomas and sessile serrated lesions. This procedure should be able to prevent colorectal cancer by detecting and removing those precursor lesions. After adenoma or sessile serrated lesion resection, individuals are considered to be at high risk of developing metachronous lesions and colorectal cancer, and are therefore advised to undergo surveillance colonoscopy. Despite these preventive measures, post-colonoscopy colorectal cancers (PCCRCs) occur at a frequency of up to 8·6%. Chemoprevention has the potential to reduce the occurrence of metachronous adenomas and colorectal cancers. Such an anticolorectal cancer effect is known for aspirin.
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Chemoprevention has the potential to reduce the occurrence of metachronous adenomas and colorectal cancers. Such an anticolorectal cancer effect is known for aspirin. 2 Furthermore, evidence suggests that fish oils might be useful in the prevention of colorectal cancer, although the mechanism of antineoplastic activity is not fully understood. 3 The naturally occurring omega-3 polyunsaturated fatty acid C20:5n3 eicosapentaenoic acid (EPA) has clinical proof of concept as a polypreducing agent from a randomised controlled trial (RCT) in patients with familial adenomatous polyposis. 4 In The Lancet, Mark Hull and colleagues 5 aimed to assess the potential of EPA and aspirin for chemoprevention of colorectal adenomas in a high-risk population. 5 This population was defined as patients who underwent colonoscopy with polypectomy of at least three adenomas if one was at least 10 mm in size, or at least five small adenomas at colonoscopy. In a multicentre, double-blind RCT in 53 Bowel Cancer Screening Programme (BCSP) centres in England, high-risk individuals were allocated to receive EPA 2 g per day (either as free fatty acid or triglyceride), aspirin 300 mg per day, or both, or neither, for 12 months. Nearly 5 years were required to enrol 709 participants, who were allocated in a 1:1:1:1 ratio to one of the four treatment groups. Adenoma outcome data were available for 640 (90%) participants. The primary endpoint was the adenoma detection rate (ADR; the percentage of participants with any adenoma) at 1 year surveillance colonoscopy, which was 62% overall, with no evidence of an effect of EPA (risk ratio [RR] 0·98, 95% CI 0·87-1·12) or aspirin (RR 0·99, 0·87-1·12). Although ADR was not reduced in individuals using EPA or aspirin, on the basis of the secondary analyses, the authors concluded that this study does provide evidence of chemopreventive activity of both agents, which was colorectal adenoma subtype selective and site selective. Aspirin was effective at reducing the mean total number of adenomas per participant (MAP; incidence rate ratio [IRR] 0·78, 95% CI 0·68-0·90), and the number of adenomas in the rightsided colon. EPA resulted in a reduced MAP in the left colorectum compared with placebo (IRR 0·75, 0·60-0·94) but not total MAP (IRR 0·91, 0·79-1·05). The authors suggest that these results could translate into a clinically meaningful decrease in long-term colorectal cancer risk.
ADR is a quality parameter that, when increased by regular feedback as an incentive, reduces subsequent colorectal cancer risk. 6 In this study, the study drugs did not have a significant effect on this quality measure, and the effect of MAP reduction on future risk of colorectal cancer is unknown. Both measures are surrogates of colorectal cancer incidence and mortality, which should be considered ultimate endpoints for chemoprevention trials. This last point is of paramount importance because, at least in patients with Lynch syndrome, the effect of aspirin on cancer development might not be primarily mediated through adenoma prevention. 7 The exact impact on clinical practice is as yet unclear. The use of chemoprevention medications in high-risk populations could potentially be useful either to reduce the PCCRCs or to reduce the burden of surveillance colonoscopies. However, most PCCRCs seem to result from missed lesions or incompletely resected lesions, 1 which are reasons for emerging interest in colonoscopy quality improvement. 8 Instead of aiming to reduce PCCRCs, the study by Hull and colleagues 5 aimed to assess the effect of EPA and aspirin on new metachronous adenomas. Although this study was embedded in the quality-assured English BCSP, an ADR of 62% for surveillance 1 year after clearing colonoscopy is remarkably high, 9 even for a high-risk population. This result suggests these adenomas might be mostly synchronous and not newly grown lesions, and could have been detected and resected at baseline colonoscopy as well.
Could the results possibly support further lengthening of the colonoscopy surveillance intervals or rather use of aspirin and EPA instead of surveillance colonoscopies? Based on the study results, after 1 year of daily medication use, there was no effect on the schedule of subsequent surveillance colonoscopy. To reduce the risk of metachronous lesions, only in the UK the highestrisk groups are recommended for 1 year surveillance, 10 whereas other European Union countries and the USA provide a 3 year recommendation. 11, 12 Ongoing trials are assessing potential further extension of the interval up to 5 years. 13 Before recommending long-term use of chemopreventive medication, several key questions should be answered. Would patients be willing to take daily medication to prevent precursor lesions and maybe colorectal cancer in the far future? The low inclusion rate (less than three patients per centre per year) suggests this might be questionable. Although EPA and aspirin were generally well tolerated, the proportion of gastrointestinal adverse events (38%) was high in participants receiving EPA alone. Compliance to taking the medications daily in the long run might be relatively low.
14 Besides an appropriate risk-benefit analysis, costeffectiveness analyses should address the question of whether daily use of aspirin and EPA would be less costly and more effective than regular surveillance colonoscopy.
The road to a paradigm shift to taking chemoprevention medications instead of, or alongside, surveillance colonoscopies to prevent colorectal cancer is still long. In the near future, personalised risk stratification and more accurate non-invasive screening tests seem more appropriate measures to reduce the number of unnecessary surveillance colonoscopies. This strategy might help to select only the individuals that need interventional colonoscopies-ideally, only those individuals with colorectal lesions that are on the verge of becoming malignant.
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